Munich - Delayed Quote EUR

Nanobiotix SA (5NRA.MU)

3.2400

0.0000

(0.00%)

At close: December 23 at 8:18:24 AM GMT+1

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics," scheduled to take place

GlobeNewswire 8 days ago

NBTX
Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Paris, France, December 11, 2024Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical

GlobeNewswire 14 days ago

NBTX
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23 months median Overall Survival from date of diagnosis was observed in 22 patients with locally advanced or borderline resectable pancreatic cancerUS FDA approved protocol amendment to launch new cohort evaluating RT-activated NBTXR3 combined with standard-of-care concurrent chemotherapy and recruitment is ongoingFull data from the completed do

GlobeNewswire 16 days ago

NBTX
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submissionAdded expert industry leaders to Supervisory Board, further strengthening support for the Company’s long-term growth strategyNBTXR3 program update from pancreatic cancer study and lung cancer study with MD Anderson expected 4Q 2024 and 1H 2025, respectivelyUpdate on expansion of product portfolio to include disruptive nanotherapeutic platfor

GlobeNewswire last month

NBTX
NANOBIOTIX to Participate in Multiple Investor Conferences in November

~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company managem

GlobeNewswire last month

NBTX
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapySeveral clinical milestones expected over the next 12-18 months including updated data in pancreatic, and head and neck cancer, and initial data in esophageal and lung cancer€66.3 million in cash and cash equivalents as of June 30, 2024, with a cash runway extended i

GlobeNewswire 3 months ago

NBTX
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Dr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boardsMs. Anat Naschitz, proven life science investor and entrepreneur; co-founder of OrbiMed Israel PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment po

GlobeNewswire 3 months ago

NBTX
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event. H.C. Wainwright 26th Annual Global Invest

GlobeNewswire 3 months ago

NBTX
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Sh

GlobeNewswire 6 months ago

NBTX
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

Figure 1 Best Change in All Target Lesions Diameter Sum from Baseline Figure 2 Best Change in All Target Lesions Diameter Sum from Baseline Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in

GlobeNewswire 6 months ago

NBTX
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, at ASCO 2024Following the ASCO presentation, Nanobiotix will host an investor event on Sunday, June 2nd at 12:00 PM EDT / 6:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., May 28, 2

GlobeNewswire 6 months ago

NBTX
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event. Jefferies Global Healthcare Conference Date: Wednesday, June

GlobeNewswire 6 months ago

NBTX
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. First Quarter Financial Updates Cash and Cash Equivalents: Based on the current operating plan and financial projections, Nan

GlobeNewswire 7 months ago

NBTX
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Updated NBTXR3 Global Development Pipeline Visualization (as of May 21, 2024) *Janssen assumed responsibility for operations in Asia after securing global rights to NBTXR3 in China and Other Asian markets from former Nanobiotix collaborator LianBio. Nanobiotix and Janssen have also aligned to intent to transfer the global sponsorship. Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3Alignment

GlobeNewswire 7 months ago

NBTX
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CESTPARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets ope

GlobeNewswire 7 months ago

NBTX
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage

GlobeNewswire 7 months ago

NBTX
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study

GlobeNewswire 7 months ago

NBTX
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CESTPARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023,

GlobeNewswire 8 months ago

NBTX
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapyConfirmation of injection feasibility and favorable safety profile in completed Phase 1 dose escalation part of the study support potential for later stage development of NBTXR3 for the treatment of patients with inoperable, recurrent NSCLC who are amenable to re-irradiationThe dose expansion part of

GlobeNewswire 8 months ago

NBTX
Nanobiotix to Present at Upcoming Investor Conferences in March

PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in fireside chats at the upcoming Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference. Please see below for details on each event. Leerink P

GlobeNewswire 9 months ago

NBTX

Performance Overview

Return	5NRA.MU	CAC 40
YTD	-50.53%	-3.45%
1-Year	-46.89%	-3.78%
3-Year	-53.71%	+2.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nanobiotix SA (5NRA.MU)

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Voting Rights and Shares Capital of the Company

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

NANOBIOTIX to Participate in Multiple Investor Conferences in November

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Nanobiotix to Present at Upcoming Investor Conferences in March

Performance Overview